INTRODUCTION
The most important request for human but also veterinary vaccines is their effectiveness to induce an intensive immune response which is able to protect the organism against specific infectious disease. However, very important is also the safety of the vaccines. Inactivated vaccines are preferred at present, though these ones compared with live vaccines are not enough immunogenic. The efficacy of inactivated vaccines may be potentiated by adjuvants. Unfortunately the use of adjuvants is often connected with local and systemic secondary effects. In veterinary medicine mainly aluminium compounds (aluminium hydroxide and aluminium phosphates) are used as adjuvants previously, although their adjuvant activity does not achieve the level of oil adjuvants. In addition the subcutaneous application of aluminium adjuvants can result in some recipients, particularly in cats, in the development of fibrosarcoma (Hendrick and Brooks, 1994; Holst et al., 2001 ; Carroll et al., 2002 ). An adjuvant of the oil-in-water type (O/W) (Süliova et al., 1999) , based on fully metabolisable (Bomford, 1981) isopropyl palmitate (IPP) -isopropylester of palmitic acid was developed in our laboratory. This adjuvant has excellent properties ; however, its disadvantage is that it can be used only for resuscitation of lyophilised vaccines and not for potentiation of liquid inactivated vaccines.
The only permitted adjuvant except aluminium compounds in human medicine is the MF59 formulation, an adjuvant of O/W type based on squalene as lipid component and detergents Tween 80 and Span 85. Just squalene and squalane originated by saturation of squalene are the objects of interest of many laboratories which are engaged in the research of new adjuvant formulations. Both lipoid compounds occur naturally in higher amounts in the shark liver.
A new experimental adjuvant based on squalene (experimental squalene adjuvant -ESA) was developed in our laboratory; its harmlessness and local reactogenity was tested on laboratory animals . The ability of ESA to potentiate rabies vaccine was tested also on laboratory animals . In this work are presented the first results of the verification of the ESAadjuvanted rabies vaccine effectiveness on target animal species -domestic dogs and cats.
MATERIAL AND METHODS

Animals:
-Young domestic dogs of different breed (age: 3-6 months) and of both sexes, non-vaccinated against rabies before (10 dogs in group total 30 animals) were used in our experiment. The rabies antibodies titres had been attested before the dogs were choosen into the experiment; only dogs without rabies antibodies were selected.
-Domestic cats of different breed (age: 3-24 months) and of both sexes, non-vaccinated against rabies before (7 cats in group, together 21 animals) were used in the experiment. The rabies antibodies titres had been attested before the cats were choosen into the experiment. The cats had been examined also on the presence of antibodies against feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV) antigen. All cats were negative, so they were suitable for this experiment. 
Vaccines used in the experiment:
Inactivated rabies vaccine (V) was obtained from MEVAK Comp. Nitra (Slovak Republic). The rabies virus had been cultivated in cell line BHK-21/13S and was inactivated with ß-propiolactone. It was revoked for experimental purposes before production of the commercial vaccine, i.e. before the addition of aluminium hydroxide which performs as adjuvant in the commercial veterinary rabies vaccine. The virus titer before inactivation was 10 6,5 MICLD 50 /0.03 mL.
The volume of adjuvant in the vaccine was replaced with equal portion of phosphate buffer of pH = 7.4.
Inactivated rabies vaccine with aluminium hydroxide adjuvant (V-Al) was obtained from MEVAK Comp. Nitra (Slovak Republic). It is the commercial Rabicell vaccine in which the inactivated rabies antigen is associated with aluminium hydroxide gel (adjuvant). The vaccine was prepared from the same operating batch as the inactivated vaccine (V). The suspension was revoked before the vial filling.
Inactivated rabies vaccine with experimental squalene adjuvant (V-ESA) was prepared according to Süli et al. (2004) by one step at low temperature. The basis of the adjuvanted vaccine emulsion was the above mentioned inactivated virus suspension from the MEVAK Comp. Nitra (Slovak Republic) from the same operating batch as both previous V and V-Al vaccines. The experimental lipoid adjuvant is an oil-in-water type emulsion based on squalene as oil component. The definitive concentration of squalene in the vaccine was 5%. Detergents Poloxamer 105 (definitive concentration 4%) and Abil-care (definitive concentration 2%) were used. The Abil-care detergent allows to prepare the adjuvanted vaccine at lower temperature (37 o C). It is important because of the assurance of the maintenance of the rabies antigen integrity in vaccine. The water component was the very inactivated rabies virus suspension (inactivated rabies vaccine -V) in a definitive concentration of 89%. The procedure for preparation is described in detail in the article by Süli et al. (2004) .
Blood sampling: -Blood samples from dogs were obtained before vaccination (day 0), further on days 14, 30, 90 and 450 after vaccination.
-Blood samples from cats were obtained before vaccination (day 0), further on days 14 and 30 after vaccination.
Serological examination of FIV antibodies and FeLV antigen:
The specific antibodies against FIV and the FeLV antigen were determined by commercial rapid diagnostic test SNAP COMBO TEST FeLV Ag / FIV Ab (IDEXX, Canada).
Determination of rabies antibodies levels:
Levels of rabies antibodies were determined by rapid fluorescence focus inhibition test (RFFIT) according to Smith et al. (1973) .
Statistical evaluation of rabies antibodies titres results was carried out by means of the Student's t-test.
RESULTS AND DISCUSSION
The results were evaluated according to the WHO recommendation (1992) , that the vaccination is succesful when the level of rabies antibodies after vaccination is minimum 0.5 international units in 1 cm 3 (IU/cm 3 ) of sera.
The examination of rabies antibodies in domestic dogs after vaccination with different vaccines (Table 1) showed that the antibodies production begins on day 14, but its level is still insufficient to protect the animals. The highest level of antibodies was detected on day 30 and on day 90 was only slightly reduced. The protection of dogs after vaccination with the vaccine with no adjuvant was already deficient on day 450. A boundary value of antibody titres after vaccination with commercial aluminium-hydroxide adjuvanted rabies vaccine was detected. The ESA-adjuvanted vaccine ensured the protection of dogs even 450 days after vaccination. Individual intra-group differences were observed which caused a relatively high standard deviation from the average value in the group. These differences might be caused by various factors influencing the vaccination results. According to Mansfield et al. (2004) the immune response of dogs against rabies vaccination is influenced e.g. by vaccine selection, by vaccination periods (when more doses are applied or at annual vaccination), by sampling for examination, by the age of dogs, even by the country of the dog's origin. The influence of vaccine choice was eliminated by the fact that all vaccines used in the experiment had been prepared from the same operating batch of the virus suspension, so the difference in the vaccine efficacy might be caused by the presence or by the quality of adjuvant. The vaccination and blood sampling were performed in all experimental groups at the same time. Young dogs of both sexes were chosen into the experiment and they were distributed equally into groups. Several dogs in the group, vaccinated by virus suspension without adjuvant, had achieved the requested protection level not even at day 30 and in the next period the titer of rabies antibodies decreased little by little. There was one such recipient in the group vaccinated by aluminium hydroxide adjuvanted vaccine. The most effective seems to be the vaccine with the experimental adjuvant. The average titres were significantly higher in all examined terms, on day 30 and 90 cca 3.5 times in comparison with the non-adjuvanted vaccine. All animals in the group had been sufficiently immunized and the high titres of rabies antibodies survived up to the 450 th day. However, there were also 2 from 10 animals with rabies antibodies below the protective level. It is necessary to realise that in this experiment a primovaccination of dogs was performed. It remains an open question if one dose of experimental adjuvanted vaccine is enough to provide the protective level of rabies antibodies the throughout whole year. This question is controvert, according to some researchers a next vaccine dose after primovaccination is needed in order to assure the protection of animals (Sage et al., 1993; Almeida et al., 1997) . The usual vaccination scheme -one dose of rabies vaccine per yearoffers a better protection to older dogs than young ones (Hogen Esch et al., 2004) . However, very old animals can have an already weakened immune system and increased risk of insufficient protection (Mansfield et al., 2004) .
The experimental groups of cats were formed using similar principles as in dogs. The cats were distributed equally into the groups according to age and sex. Since it is not compulsory to vaccinate the cats against rabies, older animals could be integrated into the experiment, as well. The cats' immune system may be influenced by immunodeficient diseases i.e. by the presence of feline immunodeficiency virus (FIV) or by feline leukaemia virus (FeLV). As into the experiment were chosen village cats which are partially free living, all experimental cats had been tested for these diseases before start of the experiment. None of cats were infected. Table 1 The cats from our experiment were watched long-time after the experiment. The owners did not observe any changes on them. The results in Table 2 show that the adjuvanted vaccines are more effective also for cats as for dogs. A significant increase of vaccine efficacy (p £ 0.01) was caused only by the ESA, but the level of rabies antibodies necessary for the protection of animals against rabies (over 0.5 IU/cm 3 ) was achieved also by other vaccines used in the experiment. Since the average titer value of rabies antibodies after application of ESA-adjuvanted vaccine was higher compared to the commercial aluminiumadjuvanted vaccine, the difference was not significant. (Rife et al., 1990) .
Blood sampling in cats is a procedure often hindered because of the nature of these animals (vagancy, aggression). The owners did not agree with repeated sampling after longer intervals. This is the reason why further examination of rabies antibodies after vaccination was impossible. Literature data are also incomplete because the cats vaccinated against rabies are mostly bred closely, i.e. they are non-stray animals and they are watched. The experiments are hindered also by juridical regulations, even though the result of our experiment was in fact rabies immunization of animals.
The experimental rabies vaccine with squalene adjuvant was developed for domestic animals (first of all for dogs and cats). Testing on laboratory animals showed sufficient efficacy of this vaccine, better than the commercial ones . It is needed to continue in verification of the properties of the experimental adjuvanted rabies vaccine on a greater number of domestic animals, but the first results presented in this work suggest suitable properties of the vaccine.
